Stoke Therapeutics, Inc. (Nasdaq: STOK) has announced the initiation of a global Phase 3 registrational study, named EMPEROR, for their lead investigational medicine, zorevunersen, aimed at treating Dravet syndrome. Following successful regulatory alignment with the FDA, EMA, and Japan's PMDA, the study is set to commence in the second quarter of 2025. This strategic move is bolstered by a collaboration with Biogen, which enables commercialization capabilities for rare genetic diseases. Stoke retains exclusive rights in the U.S., Canada, and Mexico, with Biogen covering the rest of the world. The anticipated data readout in the second half of 2027 is expected to support global regulatory filings, positioning zorevunersen as a potential first-in-class disease-modifying treatment for Dravet syndrome.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.